PE Tech Report


Like this article?

Sign up to our free newsletter

Advent Venture Partners closes first life sciences venture fund

Advent Venture Partners has held the final close of a USD120m (GBP75m) venture capital fund, to be called Advent Life Sciences.

The fund will be managed by general partners Shahzad Malik and Raj Parekh, and is the first life sciences-focused fund raised by the firm.
The fund will invest predominantly in early- and mid-stage life sciences companies in the UK, Europe and the US.

Advent Life Sciences will back companies that have a first or best-in-class approach in a range of sectors within life sciences, including new drug discovery, enabling technologies, med tech and diagnostics.
Parekh says: “We are pleased to have closed our first life sciences fund at this level in an environment of unprecedented difficulty for raising European venture funds. We appreciate the support that our LPs have shown to the team and the sector, and we look forward to investing this fund at such an opportune time in the cycle.”
The fund was raised with the participation of the UK Future Technologies Fund, managed by the European Investment Fund, which invests in a range of technologies such as life sciences, digital technology, and advanced manufacturing.

Like this article? Sign up to our free newsletter




Blackstone Private Equity